NEW YORK , Aug. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the "Class Period"), of the important August 29, 2025 lead plaintiff deadline. So what: If you purchased Petco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Investors can contact the law firm at no cost to learn more about recovering their losses ​

Investors can contact the law firm at no cost to learn more about recovering their losses

AUSTIN, Texas--(BUSINESS WIRE)--Cleveland Krist PLLC is proud to announce that associate Lourdes “Lulu” Ortiz has been named to the 2025 Lawdragon 500 X – The Next Generation list, which celebrates exceptional early-career legal professionals that are shaping the future of the profession. The 500 X spotlights lawyers who “provide a forecast of the fascinating future of global law practice.” Now in its third year, the guide recognizes young lawyers who have made an impact through significant mat.

Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses

Walmart expands associate discount card program to cover 95% of regularly priced store items, adding all food categories effective immediately.

CoreWeave's rapid revenue growth is overshadowed by persistent losses, heavy dilution, and unsustainable spending fueled by expensive, high-interest debt. The company's capital expenditures far exceed revenue, with more than $10 billion in debt and rising interest costs now surpassing $1 billion annually. Declining GPU rental prices and fierce competition from cloud giants like Microsoft, Google, and Amazon further limit CoreWeave's upside and margin potential.

The leading regional bank will consolidate two offices in this move to their new location. MEMPHIS, Tenn.

Two Republican U.S. senators called for a congressional investigation into Meta Platforms on Thursday after Reuters exclusively reported on an internal policy document that permitted the company's chatbots to “engage a child in conversations that are romantic or sensual.”

Repligen Corporation's Q2 results beat revenue expectations driven by strong revenue growth from consumables and biopharma sales. The company has diversified its product portfolio and customer base through a series of acquisitions and new launches, reducing its reliance on any single customer. RGEN stock is down 60% from its highs in the summer of 2021, and Repligen has a pristine balance sheet.

Target and Ulta Beauty said Thursday (Aug. 14) that they have mutually agreed not to renew their shop-in-shop partnership when the current agreement expires in August 2026. The Ulta Beauty at Target experience, which offers access to beauty products and lets customers link their Ulta Beauty Rewards and Target Circle accounts, will continue in Target stores and on Target.

SS&C ALPS Advisors announced distributions for its midstream ETFs, underscoring income stability and growth for investors in times of broad market volatility. The Alerian MLP ETF (AMLP) and the Alerian Energy Infrastructure ETF (ENFR) declared third quarter 2025 distributions this week.

CGUS is an actively managed U.S. equities-focused vehicle bringing together growth and income. CGUS has outperformed the S&P 500 index since my September 2024 article. Its returns since inception in 2022 are also confidently higher than IVV's. With the portfolio downsized since September 2024, CGUS has become growthier, which secures its edge over IVV. There are minor issues on the quality front though.

NEW YORK , Aug. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Replimune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NetEase, Inc. (NASDAQ:NTES ) Q2 2025 Earnings Conference Call August 14, 2025 8:00 AM ET Company Participants Bill Pang - Vice President of Corporate Development Lei Ding - Founder, CEO & Director Conference Call Participants Alicia Yap - Citigroup Inc., Research Division Felix Liu - UBS Investment Bank, Research Division Jialong Shi - Nomura Securities Co. Ltd., Research Division Lincoln Kong - Goldman Sachs Group, Inc., Research Division Ritchie Sun - HSBC Global Investment Research Xiaomeng Zhuang - BofA Securities, Research Division Yang Bai - China International Capital Corporation Limited, Research Division Yang Liu - Morgan Stanley, Research Division Brandi …

Archer Aviation Inc. continues to unlock massive global opportunities in the air taxi and defense sectors. The company has disappointed the market with recent aircraft design changes and pilot testing; but progress towards commercialization is still being made. Strategic partnerships, especially with Anduril, and international contracts provide near-term revenue and position Archer for commercial and defense market growth.

Schaeffer's Expiration Week Countdown subscribers saw a massive return on their investment in less than a week, thanks to our SoundHound AI Inc (NASDAQ:SOUN) August 13.50-strike call recommendation.

Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absorb drug pricing pressure. Both companies have robust profitability and R&D pipelines, but AMGN's growth record and PEGY ratio make it more appealing under current conditions.

The Trump administration's agreement to allow Nvidia Corp (NASDAQ:NVDA, ETR:NVD) and Advanced Micro Devices Inc (NASDAQ:AMD, ETR:AMD) to sell AI chips in China under export licenses, in exchange for 15% of profits, removes a key growth barrier and could spark the next phase of the AI boom, Wedbush analyst Dan Ives said. Ives called the deal “highly unusual” but said it was a “major growth catalyst” for Nvidia, AMD and the broader US Big Tech sector over the next 12 to 18 months.

I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains solid, with over $300 million in liquidity, sufficient to reach key data catalysts through 2027 despite brisk cash burn. The upcoming ALPHA3 futility analysis in 1H 2026 is a critical catalyst; positive MRD data could significantly revalue the stock from current depressed levels.